Timothy Burcham and Steven Arnold

Mar 31, 2016

Lasergen has appointed Timothy Burcham as its CTO. He will help develop the firm's sequencing platform. Burcham has been a member of the firm's scientific advisory board since 2015, and previously spent time developing and launching sequencing systems at Applied Biosystems. The firm also plans to rearrange its board to accommodate three seats from Agilent and will add Steven Arnold, a management consultant who also serves on the board at Houston Methodist Research Institute and Texas Children's Hospital Cancer Center. 

More Like This

Apr 25, 2017

Vicki DiFrancesco

Xifin has appointed Vicki DiFrancesco its chief strategy officer. DiFrancesco has more than 25 years of experience in executive leadership positions and was most recently president and CEO of Pathology Inc., a women's health laboratory acquired by Laboratory Corporation of America last year. 

Apr 20, 2017

Bill Bonello

NeoGenomics has appointed Bill Bonello as VP, treasurer, and director of corporate development. Prior to joining NeoGenomics, Bonello served as senior research analyst at Craig Hallum Capital Markets, and as senior research analyst for RBC Capital Markets. He has also served as senior VP of investor relations for Laboratory Corporation of America, managing director of equity research at Wachovia Capital Markets, and managing director of equity research at Piper Jaffray.

Apr 18, 2017

Mark Boguski

Inspirata has appointed Mark Boguski to the role of chief medical officer for precision medicine. He will oversee strategic planning and implementation of the firm's precision medicine solutions. Prior to joining Inspirata in September 2016, Boguski served as CMO and cofounder of Precision Medicine Network, where he created a molecular oncology knowledge visualization and decision support platform called Crosswalk Insight: Oncology.

Apr 17, 2017

Jordan Hubbard

Jordan Hubbard has joined Two Pore Guys as vice president of engineering, where he will oversee the development of software and hardware for the company's nanopore-based single-molecule biosensor. Previously, Hubbard served as a manager and director of engineering at Apple, and headed up the FreeBSD project, an open-source UNIX variant that became a core technology in Apple's products.

Apr 13, 2017

David Schenkein

David  Schenkein has told the board of Foundation Medicine he will not stand for reelection during the company's annual shareholders' meeting. He will retire from the board effective as of the date of the meeting. Schenkein is a member of the audit committee.
Apr 12, 2017

Patrick Balthrop

Agendia has appointed Patrick Balthrop, former CEO of Luminex, as non-executive chairman. Balthrop is a director at Oxford Immunotec, Personalis, and Concert Genetics. He's also an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. 

Apr 05, 2017

Alister Reynolds

Alister Reynolds has agreed to become CEO of SomaLogic. He is replacing Byron Hewett, who is stepping down. Reynolds has been on the company's board since 2003, and has held senior executive positions at Quest Diagnostics and its predecessor Corning.

Apr 05, 2017

Vishal Sikri

Vishal Sikri was appointed the general manager of Biocartis' US subsidiary, Biocartis US. Sikri was managing director and VP of commercial operations at Sysmex Inostics, the molecular diagnostics division of Sysmex, where he held other various roles. Prior to Sysmex, he held different senior product management positions at Abbott Laboratories. 

Apr 04, 2017

Erik Phelps

Tempus has hired Erik Phelps as executive VP and general counsel. He will be responsible for general corporate matters, strategy, and several other legal areas. Phelps comes to Tempus from electronic health records maker Epic Systems, where he also served as general counsel. He holds a JD from George Washington University Law School.

Apr 03, 2017

James Heath

The Institute for Systems Biology named James Heath its new president, effective January 2018. The current President and ISB Cofounder Lee Hood will remain on the institute's board. Heath is the Elizabeth W. Gilloon professor of chemistry at the California Institute of Technology, and a professor of molecular and medical pharmacology and codirector of the Parker Institute for Cancer Immunotherapy at the University of California, Los Angeles. He also is director of the NanoSystems Biology Cancer Center, which is funded by the National Cancer Institute. 

Mar 30, 2017

Joshua LaBaer

Joshua LaBaer has been appointed the executive director of the Biodesign Institute at Arizona State University, effective April 1. He was formerly at Harvard before joining ASU in 2009 to lead personalized medicine efforts at the institute as the university's first Virginia G. Piper Chair of Personalized Medicine, and director of the Biodesign Virginia G. Piper Center for Personalized Diagnostics. 

Mar 30, 2017

Michael Knell, Anthony Mattacchione

Bruker VP of Finance and Chief Accounting Officer Michael Knell announced he is resigning from the firm, effective April 21, in order to pursue other opportunities. Bruker CFO and Senior VP Anthony Mattacchione has assumed Knell's responsibilities as the company's principal accounting officer.

Mar 29, 2017

Alex Forrest-Hay

Metabolon has appointed Alex Forrest-Hay as VP of population health. In this position, Forrest-Hay will focus on the company's plans to expand its efforts to apply metabolomics to large population health studies. Before joining Metabolon, Forrest-Hay served as director of business development at Affymetrix. Prior to his work at Affymetrix, he served as a genomics specialist at Beckman Coulter and worked as a researcher at the University of Keele.

Mar 29, 2017

Anthony Gregg, Laurie Demmer, Elaine Lyon, Catherine Rehder

The American College of Medical Genetics has appointed Anthony Gregg as president-elect, Laurie Demmer as clinical genetics director, Elaine Lyon as laboratory molecular genetics director, and Catherine Rehder as laboratory cytogenetics director. It has also appointed Gregg, Demmer, Lyon, and Rehder to its board of directors. Gregg is currently a professor and chief of maternal-fetal medicine at the University of Florida. He also serves as the director of obstetrics at UF Health and program director of the Maternal-Fetal Medicine Fellowship. Demmer is a clinical geneticist and associate pediatric residency program director at Levine Children's Hospital/Carolinas Health Care. Lyon is currently a tenured professor of pathology at the University of Utah, and serves as chair of the departmental academic committee responsible for the department's faculty appointment. Rehder is currently the director of Duke University's Cytogenetics Laboratory and associate director of the Duke Molecular Diagnostics Laboratory.

Mar 27, 2017

Nicolas Barthelemy, Carlos Paya

Fluidigm said this week that it has appointed Nicolas Barthelemy and Carlos Paya to its board of directors. Barthelemy most recently served as president and CEO of molecular diagnostics firm Biotheranostics. He previously served as president of global commercial operations at Life Technologies and has also led the firm's cell systems division. He also serves on the board of directors of Repligen. Paya is president, CEO, and director of immunotherapy firm Immune Design. He formerly served as president of pharmaceutical firm Elan, and was VP of Lilly Research Laboratories.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.